Targeting Proliferating Cell Nuclear Antigen and Its Protein Interactions Induces Apoptosis in Multiple Myeloma Cells

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Müller, Rebekka ^a   Misund, Kristine ^a,d   Holien, Toril ^a,d   Bachke, Siri ^a   Gilljam, Karin M ^a   Våtsveen, Thea K ^a,d   Rø, Torstein B ^a,d   Bellacchio, Emanuele ^c   Sundan, Anders ^a,d   Otterlei, Marit ^a,b  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b APIM Therapeutics AS   (Norway)

^c BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^d KG Jebsen Center for Myeloma Research   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ATX 101; CASPASE; CELL PENETRATING PEPTIDE; CYCLINE; MELPHALAN; PROCASPASE 3; PROCASPASE 8; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG TARGETING; HUMAN; HUMAN CELL; LYMPHOCYTE; MOLECULARLY TARGETED THERAPY; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; PROTEIN INTERACTION; STROMA CELL; TUMOR XENOGRAFT;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CELL-PENETRATING PEPTIDES; CELLS, CULTURED; DRUG SYNERGISM; HELA CELLS; HUMANS; MELPHALAN; MICE; MICE, INBRED NOD; MICE, SCID; MICROSCOPY, CONFOCAL; MOLECULAR SEQUENCE DATA; MULTIPLE MYELOMA; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTEIN BINDING; TUMOR CELLS, CULTURED; U937 CELLS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84881146571     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0070430     Document Type: Article

References (34)

1. Palumbo A, Anderson K, (2011) Multiple myeloma. N Engl J Med 364: 1046-1060.
2. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, et al. (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111: 2516-2520.
3. Avet-Loiseau H, Magrangeas F, Moreau P, Attal M, Facon T, et al. (2011) Molecular Heterogeneity of Multiple Myeloma: Pathogenesis, Prognosis, and Therapeutic Implications. J Clin Oncol 29: 1893-1897.
4. Moldovan GL, Pfander B, Jentsch S, (2007) PCNA, the maestro of the replication fork. Cell 129: 665-679.
5. Mailand N, Gibbs-Seymour I, Bekker-Jensen S, (2013) Regulation of PCNA-protein interactions for genome stability. Nat Rev Mol Cell Biol 14: 269-282.
6. Stoimenov I, Helleday T, (2009) PCNA on the crossroad of cancer. Biochem Soc Trans 37: 605-613.
7. Alexandrakis MG, Passam FH, Pappa CA, Dambaki C, Sfakiotaki G, et al. (2004) Expression of proliferating cell nuclear antigen (PCNA) in multiple myeloma: Its relationship to bone marrow microvessel density and other factors of disease activity. Int J Immunopathol Pharmacol 17: 49-56.
8. Witko-Sarsat V, Mocek J, Bouayad D, Tamassia N, Ribeil JA, et al. (2010) Proliferating cell nuclear antigen acts as a cytoplasmic platform controlling human neutrophil survival. J Exp Med 207: 2631-2645.
9. Rosental B, Brusilovsky M, Hadad U, Oz D, Appel MY, et al. (2011) Proliferating Cell Nuclear Antigen Is a Novel Inhibitory Ligand for the Natural Cytotoxicity Receptor NKp44. J Immunol 187: 5693-5702.
10. Naryzhny SN, Lee H, (2010) Proliferating cell nuclear antigen in the cytoplasm interacts with components of glycolysis and cancer. FEBS Lett 584: 4292-4298.
11. Warbrick E, (1998) PCNA binding through a conserved motif. Bioessays 20: 195-199.
12. Gilljam KM, Feyzi E, Aas PA, Sousa MM, Muller R, et al. (2009) Identification of a novel, widespread, and functionally important PCNA-binding motif. J Cell Biol 186: 645-654.
13. Gilljam KM, Muller R, Liabakk NB, Otterlei M, (2012) Nucleotide Excision Repair Is Associated with the Replisome and Its Efficiency Depends on a Direct Interaction between XPA and PCNA. PLoS One 7: e49199.
14. Keats JJ, Chesi M, Egan JB, Garbitt VM, Palmer SE, et al. (2012) Clonal competition with alternating dominance in multiple myeloma. Blood 120: 1067-1076.
15. Egan JB, Shi CX, Tembe W, Christoforides A, Kurdoglu A, et al. (2012) Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood 120: 1060-1066.
16. Duncan JS, Whittle MC, Nakamura K, Abell AN, Midland AA, et al. (2012) Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer. Cell 149: 307-321.
17. Aas PA, Otterlei M, Falnes PO, Vagbo CB, Skorpen F, et al. (2003) Human and bacterial oxidative demethylases repair alkylation damage in both RNA and DNA. Nature 421: 859-863.
18. Holien T, Vatsveen TK, Hella H, Waage A, Sundan A, (2012) Addiction to c-MYC in multiple myeloma. Blood 120: 2450-2453.
19. Matyus L, (1992) Fluorescence resonance energy transfer measurements on cell surfaces. A spectroscopic tool for determining protein interactions. J Photochem Photobiol B 12: 323-337.
20. Otterlei M, Bruheim P, Ahn B, Bussen W, Karmakar P, et al. (2006) Werner syndrome protein participates in a complex with RAD51, RAD54, RAD54B and ATR in response to ICL-induced replication arrest. J Cell Sci 119: 5137-5146.
21. Xia Z, Liu Y, (2001) Reliable and global measurement of fluorescence resonance energy transfer using fluorescence microscopes. Biophys J 81: 2395-2402.
22. Misund K, Baranowska KA, Holien T, Rampa C, Klein DC, et al. (2013) A Method for Measurement of Drug Sensitivity of Myeloma Cells Co-cultured with Bone Marrow Stromal Cells. J Biomol Screen.
23. Sakurai S, Kitano K, Yamaguchi H, Hamada K, Okada K, et al. (2005) Structural basis for recruitment of human flap endonuclease 1 to PCNA. EMBO J 24: 683-693.
24. Azab AK, Runnels JM, Pitsillides C, Moreau AS, Azab F, et al. (2009) CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood 113: 4341-4351.
25. Meads MB, Gatenby RA, Dalton WS, (2009) Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer 9: 665-A674.
26. Ciccia A, Nimonkar AV, Hu Y, Hajdu I, Achar YJ, et al. (2012) Polyubiquitinated PCNA Recruits the ZRANB3 Translocase to Maintain Genomic Integrity after Replication Stress. Mol Cell 47: 396-409.
27. Warbrick E, (2006) A functional analysis of PCNA-binding peptides derived from protein sequence, interaction screening and rational design. Oncogene 25: 2850-2859.
28. Lehmann AR, Niimi A, Ogi T, Brown S, Sabbioneda S, et al. (2007) Translesion synthesis: Y-family polymerases and the polymerase switch. DNA Repair (Amst) 6: 891-899.
29. Despras E, Delrieu N, Garandeau C, Ahmed-Seghir S, Kannouche PL, (2012) Regulation of the specialized DNA polymerase eta: Revisiting the biological relevance of its PCNA- and ubiquitin-binding motifs. Environ Mol Mutagen 53: 752-765.
30. Schopf B, Bregenhorn S, Quivy JP, Kadyrov FA, Almouzni G, et al. (2012) Interplay between mismatch repair and chromatin assembly. Proc Natl Acad Sci U S A 109: 1895-1900.
31. Uwada J, Tanaka N, Yamaguchi Y, Uchimura Y, Shibahara K, et al. (2010) The p150 subunit of CAF-1 causes association of SUMO2/3 with the DNA replication foci. Biochem Biophys Res Commun 391: 407-413.
32. Punchihewa C, Inoue A, Hishiki A, Fujikawa Y, Connelly M, et al. (2012) Identification of Small Molecule Proliferating Cell Nuclear Antigen (PCNA) Inhibitor That Disrupts Interactions with PIP-box Proteins and Inhibits DNA Replication. J Biol Chem 287: 14289-14300.
33. Tan ZQ, Wortman M, Dillehay KL, Seibel WL, Evelyn CR, et al. (2012) Small-Molecule Targeting of Proliferating Cell Nuclear Antigen Chromatin Association Inhibits Tumor Cell Growth. Mol Pharmacol 81: 811-819.
34. Chan KS, Koh CG, Li HY, (2012) Mitosis-targeted anti-cancer therapies: where they stand. Cell Death Dis 3: e411.